Journal articles
Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?
Abstract : The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low- grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan–bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow- up of 23 months after the end of the bevacizumab–irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan–bevacizumab can improve progression-free survival in children with LGG.
Cited literature [14 references]
https://hal-amu.archives-ouvertes.fr/hal-01478943
Contributor : Dominique Figarella-Branger <>
Submitted on : Tuesday, February 28, 2017 - 2:58:59 PM
Last modification on : Monday, February 15, 2021 - 3:00:10 PM
Long-term archiving on: : Monday, May 29, 2017 - 3:43:18 PM
Contributor : Dominique Figarella-Branger <>
Submitted on : Tuesday, February 28, 2017 - 2:58:59 PM
Last modification on : Monday, February 15, 2021 - 3:00:10 PM
Long-term archiving on: : Monday, May 29, 2017 - 3:43:18 PM
File
Heng et al_2016.pdf
Publisher files allowed on an open archive